Inge Marie Svane

52PUBLICATIONS
226CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (52)

|Jul 23, 2026
Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.

|Jun 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

|May 18, 2026
Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

|Mar 05, 2026
Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis.

Rikke Boedker Holmstroem, Ane Soegaard Teisner, Mark Wilhelmus Dirk Sweep

|Feb 12, 2026
Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform.

Silje Kjølle, Mario Presti, Jéssica de Pina Roque

|Dec 14, 2025
Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.

Sidsel Pedersen, Mikkel Byrdal, Evelina Martinenaite

Pageof 9

Frequent Collaborators

25 joint publications

Marco Donia

11 joint publications

Eva Ellebaek

9 joint publications

Mads Hald Andersen

9 joint publications

Özcan Met